{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:49:02Z","timestamp":1769838542757,"version":"3.49.0"},"reference-count":77,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1080\/10428190500085024","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T04:14:41Z","timestamp":1126066481000},"page":"951-966","source":"Crossref","is-referenced-by-count":27,"title":["The adverse prognostic impact of advanced age in multiple myeloma"],"prefix":"10.1080","volume":"46","author":[{"given":"Linda","family":"Mileshkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H Miles","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2009,8,3]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702188"},{"key":"CIT0002","first-page":"299","volume":"127","author":"Phekoo KJ","year":"2004","journal-title":"A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-3-343"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S1040-8428(01)00102-0"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00301.x"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01651.x"},{"key":"CIT0011","first-page":"1839","volume":"7","author":"Corrado C","year":"1989","journal-title":"J Chin Oncol"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"CIT0015","first-page":"1875","volume":"348","author":"Child JA","year":"2003","journal-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multi-ple myeloma. N Engl J Med"},{"issue":"1","key":"CIT0016","first-page":"396a","volume":"94","author":"Fermand JP","year":"1999","journal-title":"Blood"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0881"},{"key":"CIT0019","first-page":"42a","volume":"102","author":"Barlogie B","year":"2003","journal-title":"Blood"},{"key":"CIT0020","first-page":"1709","volume":"18","author":"Extermann M","year":"2000","journal-title":"What threshold for adjuvant therapy in older breast cancer patients? J Chin Oncol"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/32.2.171"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.135.2.182"},{"key":"CIT0024","first-page":"2150","volume":"97","author":"DeMichele A","year":"2003","journal-title":"Norman S. Older age predicts a decline in adjuvant chemotherapy recommen-dations for patients with breast carcinoma: Evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700917"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200219020-00002"},{"key":"CIT0027","first-page":"708","volume":"18","author":"Fine HA","year":"2000","journal-title":"Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Chin Oncol"},{"key":"CIT0028","first-page":"278","volume":"1","author":"Bertini M","year":"2001","journal-title":"The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1007\/s002770000255"},{"key":"CIT0031","first-page":"149","volume":"31","author":"Rao AV","year":"2004","journal-title":"Geriatric assessment and comorbidity. Semin Oncol"},{"key":"CIT0033","first-page":"1255","volume":"13","author":"Yellen SB","year":"1995","journal-title":"J Chin Oncol"},{"key":"CIT0034","first-page":"1766","volume":"86","author":"Yellen SB","year":"1994","journal-title":"Age and clinical decision making in oncology patients. J Natl Cancer Inst"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.050"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2004.04.002"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5394.2000.83004.x"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050365"},{"key":"CIT0041","first-page":"729","volume":"68","author":"Ludwig H","year":"1982","journal-title":"Epidemiologic and age-dependent data on multiple myeloma in Austria. J Natl Cancer Inst"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-001-0388-5"},{"key":"CIT0043","first-page":"132","volume":"65","author":"Suguro M","year":"2000","journal-title":"High serum lactate dehydrogenase level predicts short survival after vincristine-doxorubicin-dexamethasone (VAD) salvage for refractory multiple myeloma. Am J Hematol"},{"key":"CIT0045","first-page":"257","volume":"60","author":"Matzner Y","year":"1978","journal-title":"Polliack A. Prognostic factors in multiple myeloma: A retrospective study using conventional statistical methods and a computer program. Acta Haematol"},{"key":"CIT0046","first-page":"198","volume":"45","author":"Hannisdal E","year":"1990","journal-title":"Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol"},{"key":"CIT0047","first-page":"183","volume":"30","author":"Pennec Y","year":"1983","journal-title":"Critical study of staging in multiple myeloma. Scand J Haematol"},{"key":"CIT0048","first-page":"965","volume":"66","author":"Froom P","year":"1990","journal-title":"Multiple myeloma in the geriatric patient. Cancer"},{"key":"CIT0052","first-page":"589","volume":"83","author":"Fratino L","year":"1998","journal-title":"The impact of cancer on the physical function of the elderly and their utilization of health care. G.I.O. Ger (Gruppo Italiano Oncologia Geria-trica). Cancer"},{"key":"CIT0053","first-page":"316","volume":"79","author":"Cohen HJ","year":"1985","journal-title":"Southeastern Cancer Study Group experience. Am J Med"},{"key":"CIT0054","first-page":"272","volume":"31","author":"Cohen HJ","year":"1983","journal-title":"Effects of age on responses to treatment and survival of patients with multiple myeloma. J Am Geriatr Soc"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1994.tb06866.x"},{"key":"CIT0056","first-page":"1397","volume":"46","author":"Lazarus HM","year":"1980","journal-title":"Clinical course and electron microscopic studies of bone marrow plasma cells. Cancer"},{"key":"CIT0058","first-page":"117","volume":"86","author":"Clough V","year":"1977","journal-title":"Multiple myeloma in a young woman. Ann Intern Med"},{"key":"CIT0059","first-page":"104","volume":"46","author":"Khunger JM","year":"2003","journal-title":"Multiple myeloma presenting as primary non-secretory plasma cell leukemia. Indian J Pathol Microbiol"},{"key":"CIT0060","first-page":"177","volume":"66","author":"Chen CC","year":"2003","journal-title":"J Chin Med Assoc"},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.12.030"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(05)80205-9"},{"key":"CIT0065","first-page":"328","volume":"43","author":"Palva IP","year":"1989","journal-title":"Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. Eur J Haematol"},{"key":"CIT0066","first-page":"172","volume":"72","author":"Gulbrandsen N","year":"2004","journal-title":"Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences. Eur J Haematol"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026548226770"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3163"},{"issue":"3","key":"CIT0070","first-page":"265","volume":"15","author":"Bjorkstrand B","year":"1994","journal-title":"Prognostic factors in autologous stem cell transplantation for multiple myeloma: An EBMT Registry Study. European Group for Bone Marrow Trans-plantation. Leuk Lymphoma"},{"key":"CIT0071","first-page":"18","volume":"15","author":"Kusnierz-Glaz CR","year":"1997","journal-title":"Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hemato-logic malignancies. J Chin Oncol"},{"key":"CIT0075","first-page":"267","volume":"73","author":"Magagnoli M","year":"2003","journal-title":"Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lympho-ma: survey from a single institution. Am J Hematol"},{"key":"CIT0076","first-page":"300","volume":"88","author":"Villela L","year":"2003","journal-title":"Jr., Martino R, Valcarcel D, Altes A, Briones J, Gomez M, Brunet S. Low transplant related mortality in older patients with hematolo-gic malignancies undergoing autologous stem cell transplantation. Haematologica"},{"key":"CIT0077","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704288"},{"key":"CIT0078","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"Siegel DS","year":"1999","journal-title":"Blood"},{"key":"CIT0079","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02976.x"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702736"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.01979.x"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.731"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20030"},{"key":"CIT0085","first-page":"142","volume":"93","author":"Prince HM","year":"1996","journal-title":"Peripheral blood progenitor cell collections in multiple myeloma: Predictors and management of inadequate collec-tions. Br J Haematol"},{"key":"CIT0086","first-page":"2495","volume":"349","author":"Attal M","year":"2003","journal-title":"Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med"},{"key":"CIT0087","first-page":"3447","volume":"102","author":"Maloney DG","year":"2003","journal-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood"},{"key":"CIT0088","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0131"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199911183412102"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.15"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1045"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.984"},{"key":"CIT0094","first-page":"4444","volume":"21","author":"Dimopoulos MA","year":"2003","journal-title":"Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Chin Oncol"},{"key":"CIT0095","first-page":"4319","volume":"20","author":"Rajkumar SV","year":"2002","journal-title":"Combination therapy with thalidomide plus dexa-methasone for newly diagnosed myeloma. J Chin Oncol"},{"key":"CIT0096","first-page":"16","volume":"21","author":"Weber D","year":"2003","journal-title":"Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Chin Oncol"},{"key":"CIT0098","first-page":"3377","volume":"8","author":"Neben K","year":"2002","journal-title":"Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Chin Cancer Res"},{"key":"CIT0099","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403322"},{"key":"CIT0101","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200401"},{"key":"CIT0102","first-page":"207a","volume":"104","author":"Palumbo A","year":"2004","journal-title":"A., Musto P. et al. A prospective randomized trial of oral melphalan, prednisolone, thalido-mide (MPT) vs oral melphalan, prednisolone (MP): An interim analysis [abstract]. Blood"},{"key":"CIT0103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1418"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428190500085024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T09:05:18Z","timestamp":1586423118000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428190500085024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":77,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2009,8,3]]},"published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1080\/10428190500085024"],"URL":"https:\/\/doi.org\/10.1080\/10428190500085024","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}